drugset / Trial / NCT04298697
Biomarkers for Event-driven PrEP Adherence
Non-randomizedSequentialOpen-labelBasic science
Summary
This study aims to recruit 40 participants who will take the combination anti-HIV drug tenofovir+emtricitabine (TDF/FTC) at specified times. Participants will then provide biologic samples for the measurement of anti-retroviral drug concentrations in various body compartment sites. Participants will be involved in the study for up to 24 weeks.
Timeline
- Start
- 2020-02-28
- Primary completion
- 2022-08-09
- Completion
- 2022-08-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tenofovir disoproxil fumarate | Small molecule | 300 mg | — |
| Subject | emtricitabine | Other / unclassified | 200 mg | — |